Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | PHGDH | O43175 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.33 |
| ▸ | MC4R | P32245 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25754641 | 0.79 | TSHR (0.36) | SIGMAR1TSHRGAAPHGDHMGLL | |
| SCHEMBL13461316 | 0.74 | POLB (0.44) | SIGMAR1TSHRGAAPHGDHMGLL | |
| SCHEMBL25754624 | 0.74 | — | — | |
| SCHEMBL25754645 | 0.73 | HRH3 (0.40) | TSHRALDH1A1 | |
| SCHEMBL21164490 | 0.72 | POLB (0.45) | SIGMAR1TSHRGAAPHGDHMGLL | |
| SCHEMBL25754561 | 0.69 | SIGMAR1 (0.41) | SIGMAR1TSHRPHGDHMGLLALDH1A1 | |
| SCHEMBL23732159 | 0.69 | PIK3CD (0.42) | SIGMAR1TSHRGAAPHGDHMGLL | |
| SCHEMBL7899320 | 0.68 | HSD11B1 (0.48) | SIGMAR1TSHRPHGDHMGLLTMEM97 | |
| SCHEMBL13088144 | 0.68 | HSD11B1 (0.48) | SIGMAR1TSHRPHGDHMGLLTMEM97 | |
| SCHEMBL6658589 | 0.67 | SIGMAR1 (0.51) | SIGMAR1PHGDHMGLLTMEM97HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | SIGMAR1 4773/4885TSHR 331/4885GAA 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.